1. Background {#sec1}
=============

Gastric cancer is the sixth most prevalent malignant tumor worldwide and the third leading cause of cancer-related deaths. The International Agency for Research on Cancer estimated that there were about one million new cases of gastric cancer and 782685 deaths from gastric cancer in 2018 \[[@B1]\]. Upper gastric cancer, also known as proximal gastric cancer, occurs below the cardia and above a line connecting the greater and lesser curvatures, and its incidence is increasing \[[@B2]--[@B5]\]. The epidemiology, pathology, surgical treatment, and prognosis of upper gastric cancer differ from those of lower stomach cancer. Its anatomical location makes upper stomach cancer relatively difficult to find, and it lacks specific symptoms at early stages of disease. Diagnosis at a mid or late stage increases the difficulty of treatment and leads to a poor prognosis \[[@B4], [@B6], [@B7]\]. An evaluation of dysphagia may lead to an early diagnosis \[[@B8], [@B9]\]. At present, the choice of surgical treatment has changed from simple anatomy to oncology biology, immunology, and anatomy. The clinical and pathological characteristics of individual upper gastric cancer patients may be of value in choosing surgical options that will improve survival. Radical surgery is currently the most effective treatment, but the extent of lymph node dissection and the optimal surgical procedure may not be easy to determine \[[@B10]--[@B12]\]. The objective of this retrospective analysis of patient characteristics, surgical treatment, and cancer prognosis was to identify clinical, pathological, and surgical variables that were associated with improved outcomes, prognosis, and survival of those with upper gastric cancer.

2. Patients and Methods {#sec2}
=======================

2.1. Patient Selection and Study Design {#sec2.1}
---------------------------------------

A group of 2200 patients with radical surgery for gastric cancer at The First Hospital of China Medical University, Shenyang, Liaoning, China, between January 1980 and December 2012 were retrospectively evaluated. Patients with a postoperative pathological diagnosis of primary gastric adenocarcinoma, no other history of gastric surgery, no neoadjuvant therapy before surgery, and no preoperative imaging evidence of distant metastasis were eligible. All surgeries were R0 resections; postoperative pathology was evaluated by two experienced pathologists. The lymph node grouping, transfer site, and numbers were included in the pathology report. All included patients had complete follow-up data, and there was no loss of follow-up. Of the 2200 included patients, 649 had upper gastric cancer and 1551 had lower gastric cancer.

2.2. Pathological Criteria {#sec2.2}
--------------------------

The macroscopic pathology included Borrmann types 1 and 2 for local and Borrmann types 3 and 4 for infiltrative disease. Tissue growth was classified as agglomerate, nest, or diffuse. Tissue typing included highly and moderately differentiated papillary adenocarcinoma and well- and poorly differentiated tubular adenocarcinoma. Signet ring cell carcinoma, mucinous adenocarcinoma, and undifferentiated carcinoma were classified as poorly differentiated. The depth of tumor invasion involving the mucosa, submucosa, muscularis propria, subserosa, and the serosal surface and lymph node metastasis were classified following the 14^th^ edition of the Gastric Cancer Treatment Protocol of the Japanese Gastric Cancer Association. Pathological staging followed the eighth edition of the American Joint Committee on Cancer tumor, node, and metastasis (TNM) staging system.

2.3. Statistical Analysis {#sec2.3}
-------------------------

Count data were analyzed by chi-squared tests and logistic regression. Cumulative survival was analyzed and plotted by the Kaplan-Meier method; differences were evaluated with log-rank tests. Cox proportional hazard regression was used for multifactor analysis. SPSS 23.0 (IBM Corp., Armonk, NY, USA) was used for the statistical analysis, and Microsoft Excel was used for data collation. *p* \< 0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Clinicopathological Characteristics of Upper and Lower Gastric Cancers {#sec3.1}
---------------------------------------------------------------------------

Patient characteristics are shown in [Table 1](#tab1){ref-type="table"}. The ratio of male to female patients was significantly higher in upper than in lower gastric cancer patients (4.5 : 1 versus 2.4 : 1, *p* \< 0.001). The average age of upper gastric cancer patients was 61.5 years compared with 57.5 years in lower gastric cancer patients (*p* = 0.003). Three hundred and eighty-two (58.9%) of upper gastric cancers have ≥5 cm diameter compared with 605 (39%) of the lower gastric cancers (*p* \< 0.001). Diagnosis was at an early stage in 47 (7.2%) of upper gastric cancer patients and 332 (21.4%, *p* \< 0.001) of lower gastric cancer patients. The pT stages and numbers of positive lymph nodes are shown in [Table 1](#tab1){ref-type="table"}. Fewer patients with upper (35.7%) than lower (41.2%) gastric cancer were lymph node negative (*p* = 0.046). The degree of differentiation of upper cancer tissues was significantly less than that of lower gastric cancers (*p* = 0.046). The growth patterns of upper and lower gastric cancers were significantly different (*p* \< 0.001). Lymphovascular tumor emboli occurred in 172 of upper (26.5%) and 346 of lower (22.3%) gastric cancer tumors. Serosal invasion occurred in 264 of upper (40.7%) and 375 of lower (24.2%) gastric cancers (*p* \< 0.001). Recurrence and metastasis occurred in 277 cases of upper (42.7%) and 526 cases of lower (33.9%) gastric cancer (*p* \< 0.001).

3.2. Prognosis of Upper Gastric Cancer {#sec3.2}
--------------------------------------

The 1-year survival after radical surgery for upper gastric cancer was 77.8%, 3-year survival was 49.6%, and 5-year survival was 41.1%. The 1-year survival after surgery for lower gastric cancer was 85.9%, the 3-year survival was 60.0%, and the 5-year survival was 57.2% (*p* \< 0.001, [Figure 1](#fig1){ref-type="fig"}). Univariate analysis showed that the tumor diameter, macroscopic type, pTNM stage, lymphovascular tumor embolus, serosal invasion, recurrence and metastasis, and postoperative adjuvant chemotherapy were associated with upper gastric cancer prognosis. Survival decreased with pTNM stage local Borrmann type 1 and 2 tumors, smaller tumor diameter, no lymphovascular tumor emboli, no serosal invasion, and no recurrence and/or metastasis. Survival was longer in patients with adjuvant chemotherapy after surgery (Figures [2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}). After multivariate analysis, the macroscopic tumor type, recurrence and metastasis, postoperative adjuvant chemotherapy, and pTNM staging were independently associated with upper gastric cancer prognosis ([Table 2](#tab2){ref-type="table"}).

The characteristics of patients with and without lymph node metastasis are shown in [Table 3](#tab3){ref-type="table"}. Metastatic lymph nodes were not found in 231 of the 649 patients with upper gastric cancer (35.6%); 418 (64.4%) had lymph node metastasis. The male : female ratio was 6.7 : 1 in the group without and 3.75 : 1 in the group with lymph node metastasis (*p* = 0.011). Lymph node metastasis occurred in 72.5% of patients with tumors ≥ 5 cm in diameter and in 52.8% of those with tumors \< 5 cm in diameter (*p* \< 0.001); in 68.9% of patients with poorly differentiated tumors and in 58.1% of patients with well-differentiated tumors (*p* = 0.005); in 17.0% of early cancers and in 68.1% of advanced cancers (*p* \< 0.001); and in 48.4% of patients with macroscopic local tumors and in 73.3% of infiltrative tumors (*p* \< 0.001). Lymph node metastasis increased significantly with pTNM staging (*p* \< 0.001). The pN rates are shown in [Table 3](#tab3){ref-type="table"} and ranged from 17.0% for pT1 to 79.5% for pT4b tumors. Lymph node metastasis occurred in 75.8% of patients with serosal invasion and in 56.6% of those with no serosal invasion. Patient sex, age, tissue growth mode, and lymphovascular cancer embolus were not significantly different in patients with or without lymph node metastasis. Multivariate analysis and logistic regression ([Table 4](#tab4){ref-type="table"}) revealed that sex (*p* = 0.036), tumor diameter (*p* = 0.001), macroscopic type (*p* \< 0.001), pT stage (*p* \< 0.001), tissue differentiation type (*p* = 0.003), and serosal invasion (*p* = 0.034) were independently associated with lymph node metastasis of upper gastric cancer.

The survival analysis of patients with and without lymph node metastasis is shown in [Figure 4](#fig4){ref-type="fig"}. The 1-year survival of the 231 patients with no lymph node metastasis was 86.1%, 3-year survival was 69.7%, and 5-year survival was 63%. The corresponding survival rates for the 418 patients with lymph node metastasis were 73.2%, 38.4%, and 28.7% (*p* = 0.001). When pN stage was included in the analysis, 5-year survival ranged from 63.0% for pN0 to 11.3% for pN3b tumors (*p* \< 0.001) showing that survival decreased with increased pN stage. Five-year survival was ranged from 79% for pT1 to 22.2% for pT4b stage patients without metastatic lymph nodes. Five-year survival of patients with corresponding pT stages and metastatic lymph nodes ranged from 65.6% to 8.6%.

3.3. Postoperative Recurrence and Metastasis of Upper Gastric Cancer {#sec3.3}
--------------------------------------------------------------------

Tumor recurrence and metastasis occurred in 277 of the 649 patients with upper gastric cancer (42.7%). Recurrence occurred in 47.4% of patients with tumors ≥ 5 cm in diameter and in 36.0% of those with tumors \< 5 cm (*p* = 0.004). Recurrence and metastasis occurred in 12.8% of early upper gastric cancers and 45.0% of advanced stage cancers (*p* \< 0.001); 28.6% of localized tumors and 49.4% of infiltrating tumors (*p* \< 0.001); 52.3% of patients with lymphovascular cancer emboli and 39.2% who were thrombus-negative (39.2%, *p* = 0.003); and 50% of patients with serosal invasion compared with 37.7% of those with noninvasive tumors (*p* = 0.002). As shown in [Table 5](#tab5){ref-type="table"}, recurrence and metastasis increased significantly with pTNM stage, 17.8% at stage I, 27.1% at stage II, and 58.8% at stage III (*p* \< 0.001). Multivariate analysis ([Table 6](#tab6){ref-type="table"}) found that the macroscopic type (*p* = 0.045), lymphovascular tumor emboli (*p* = 0.021), and pTNM stage were independently associated with recurrence and metastasis after tumor resection.

3.4. Surgical Methods and Prognosis of Upper Gastric Cancer {#sec3.4}
-----------------------------------------------------------

D2 total gastrectomy with 1--7, 8a, 9, 10, 11p, or 12a lymph node dissection and Roux-en-Y reconstruction were performed in 333 patients. D2 proximal gastrectomy with esophagogastrostomy was performed in 281 patients, ten with jejunal interposition, and 25 with double-tract reconstruction. The spleen was preserved unless it contained metastatic lymph nodes. Better survival rates were achieved with total gastrectomy than with proximal gastrectomy (*p* = 0.029, [Figure 5](#fig5){ref-type="fig"}). One-year survival of the 333 patients with D2 total gastrectomy was 81.3%, 3-year survival was 54.4%, and 5-year survival was 45.2%. One-year survival of the 316 proximal gastrectomy patients was 75.4%, 3-year survival was 44.9%, and 5-year survival rate was 36.7%. In patients with tumors that had invaded the serosa, survival was better with total than with proximal gastrectomy (*p* = 0.045, [Figure 6(a)](#fig6){ref-type="fig"}). Survival was also better with total than with proximal gastrectomy in patients with infiltrative type upper gastric cancer (*p* = 0.028, [Figure 6(b)](#fig6){ref-type="fig"}). Differences in survival were not associated with other patient characteristics ([Table 7](#tab7){ref-type="table"}).

Twenty-one patients with total gastrectomy (6.3%) and 36 with proximal gastrectomy (11.4%) had postoperative complications. Five total gastrectomy patients experienced wound infections, three developed pneumonia, and two experienced fluid esophagitis; and intestinal obstruction, abdominal infection, and pancreatic fistula occurred in one patient each. There were seven occurrences of diarrhea, anemia, pneumothorax, and dumping syndrome. Wound infections and anastomotic leakage each occurred in eight proximal gastrectomy patients, five patients developed pneumonia, and four experienced reflux esophagitis. There were three cases of intestinal obstruction, three of abdominal infection, and two of pancreatic fistula. There were ten reports of diarrhea, anemia, pneumothorax, emphysema, and heart failure.

4. Discussion {#sec4}
=============

The biological behavior of tumors determines the occurrence, development, and pathological features of tumors. It is a sign of the nature and malignancy of tumors. The gastric cancer in different parts has great differences in biological behavior. The macroscopic type, growth pattern, and degree of tissue typing of gastric cancer can correctly reflect the biological behavior of gastric cancer, and it is a sign of malignant accumulation and invasive expansion of gastric cancer.

Diagnosis of early stage disease has been reported in only 4.3% of patients with upper gastric cancer \[[@B13]\], which is significantly less frequent than in patients with lower gastric cancer. In this series, 7.2% of the upper gastric cancers were found at an early stage, which was significantly lower than the 21.4% of early lower gastric cancer diagnoses. The proportion of tumors that were ≥ 5 cm was significantly greater in patients with upper than with lower gastric cancer; more upper than lower gastric cancer tumors were poorly differentiated. The pT stage was significantly more advanced in upper than in lower gastric cancers; infiltration was deeper; and pN stage, proportion of tumors with lymphovascular emboli, and the proportion of tumors with serosal invasion were all higher. Recurrence and metastasis after surgery were also more frequent in patients with upper than with lower gastric cancer.

The study results are consistent with previous findings that survival is worse with upper than with lower gastric cancer. In this series, 5-year survival was 41.1% in upper gastric cancer compared with 57.2% in lower gastric cancer patients ([Figure 1](#fig1){ref-type="fig"}), which is comparable to the 40% 5-year survival reported by others \[[@B14], [@B15]\]. Univariate analysis showed that the tumor diameter, macroscopic type, pTNM stage, lymphovascular tumor emboli, serosal invasion, tumor recurrence and metastasis, and postoperative adjuvant chemotherapy all affected the prognosis of upper gastric cancer. Five-year survival was 50.9% when the tumor diameter was \<5 cm and 34.1% when it was ≥5 cm; 77.9% for early and 38.0% for advanced disease; 51.4% for local and 34.2% for infiltrative tumors; 44.3% in the absence of and 31.4% in the presence of lymphovascular tumor emboli; 30.3% with and 47.5% without serosal invasion; 7.2% with and 66.2% without recurrence and metastasis; and 52.3% with and 36.0% without adjuvant therapy. Five-year survival also significantly decreased from 69.8% to 24.0% with the increase of pTNM stage from I to III. Multivariate analysis found that the macroscopic type, recurrence and metastasis, postoperative adjuvant chemotherapy, and pTNM stage were all independently associated with the prognosis of upper gastric cancer.

Most upper gastric cancers are diagnosed at a more advanced stage than lower gastric cancers; few cases of early disease are detected. The macroscopic type is generally infiltrative, the tumor diameter is large, and the tissue is poorly differentiated and has invaded the serosa. Lymph node metastasis, late pTNM stage, and recurrence and metastasis after surgery are the main contributors to a worse prognosis than that of lower gastric cancer. Adjuvant chemotherapy is known to increase the effectiveness of surgery in advanced gastric cancer \[[@B16]--[@B22]\]. Five-year survival was 52.3% in patients with adjuvant chemotherapy compared with 36.0% in those who did not receive it, which supports a recommendation for adjuvant chemotherapy in upper gastric cancer patients following resective surgery.

Lymph node metastasis has a poor prognosis in gastric cancer, which makes the removal of a sufficient number of regional lymph nodes an important component of radical surgery. Five-year survival was 28.7% in patients with and 63% in those without lymph node metastasis. The finding of lymph node metastasis in 64.3% of upper gastric cancer patients compared with 58.8% of those with lower gastric cancer is consistent with previous reports \[[@B23]\]. In this study, male sex, tumors ≥ 5 cm, poor tumor differentiation, macroscopic infiltration, and serosal invasion were more frequent in patients with lymph node metastasis. Statistical analysis found that sex, tumor diameter, macroscopic type, pT stage, tissue growth pattern, and serosal invasion were independent risk factors for lymph node metastasis of upper gastric cancer.

Gastric cancer recurs in situ or with lymph node, peritoneal, or liver metastasis or with hematogenous spread outside the liver with metastasis to other locations. Postoperative recurrence and metastasis may be related to tumor characteristics such as size, tissue type, differentiation, growth mode, pTNM staging, the extent of radical surgery, lymph node dissection, and intraoperative spread of cancer cells \[[@B24], [@B25]\]. Gastric cancer prognosis includes a high risk of recurrence and metastasis after radical gastrectomy \[[@B26]\]. Recurrence after radical gastrectomy is estimated to occur in approximately 50% \[[@B27]\], to more than 70% of patients with lymph node metastasis at diagnosis \[[@B28]\]. In this study, recurrence and metastasis occurred in 42.7% of upper gastric cancers and in 33.9% of lower gastric cancers. Recurrence and metastasis in patients with upper gastric cancer and preoperative lymph node metastasis were 54.3%, which is lower than previously reported. One-year survival of patients with postoperative recurrence and metastasis was 70.0%; the 3-year survival was 20.2%; and the 5-year survival was 7.2%, all of which were lower than the 83.6%, 71.5%, and 66.2% survival of patients without recurrence and metastasis, respectively. Recurrence and metastasis were more frequent in patients with tumors ≥ 5 cm, macroscopic infiltration, lymphovascular tumor emboli, serosal invasion, and increased pTNM stage. The macroscopic type, lymphovascular tumor emboli, and pTNM stage were independently associated with recurrence and metastasis.

Radical surgery is recommended by the Japanese Gastric Cancer Association Classification of Gastric Carcinoma fifteenth edition. D2 radical lymph node dissection is recommended, but differences of surgical procedures result in differences of the number of lymph nodes collected. It is still not clear whether total gastrectomy or proximal gastrectomy is preferred \[[@B29]\]. Total gastrectomy achieves sufficient resection and a wide range of lymph node dissection. Proximal gastrectomy preserves part of the stomach, allowing reconstruction of the digestive tract and better physiological recovery \[[@B30]\]. In upper gastric cancer surgery, dissection of lymph nodes 10 and 11b in the second station involves consideration of the spleen and possibly pancreatic body resection. However, two European randomized trials found that D2 surgery with spleen resection did not provide a survival benefit but rather increased the incidence of postoperative complications and mortality \[[@B11], [@B31]\]. A study by the Japan Clinical Oncology Group (JCOG0110) that compared splenectomy and spleen-preserving surgery did not find a significant difference in the 5-year survival in a group of over 500 gastric cancer patients (75.1% vs. 76.4%). The incidence of postoperative complications was higher in the splenectomy group (30.3%) than in the spleen-preserving group (6.7%, *p* \< 0.05). Splenectomy should be avoided in patients with total gastrectomy for upper gastric cancer that does not involve the greater curvature and is without splenic lymph node metastasis. In such patients, splenectomy increases the occurrence of complications without increasing survival \[[@B32]\]. Neither the Japanese gastric treatment guidelines nor the National Comprehensive Cancer Network recommends prophylactic splenectomy \[[@B33]\]. The JCOG9501 study, which included patients who were at high risk, found an 8.4% incidence of No. 10 lymph node metastasis \[[@B34]\]. Whether splenectomy can improve survival in patients at risk of lymph node 10 metastasis because of the extent of local invasion, invasion of the greater curvature, or clinical suspicion of lymph node 10 metastasis deserves study.

4.1. Study Strengths and Limitations {#sec4.1}
------------------------------------

The strengths include a relatively large sample size, which increased the statistical power. The retrospective design is a limitation, as the data may lack variables that could affect the results.

5. Conclusion {#sec5}
=============

Upper and lower gastric cancer patients differed in sex, age, tumor diameter, tissue type, growth pattern, macroscopic type, infiltration depth, degree of lymph node metastasis, lymphovascular tumor emboli, and postoperative tumor recurrence and metastasis. Upper gastric cancers were more aggressive, had a worse prognosis, and were more prone to recurrence and metastasis after radical gastrectomy than lower gastric cancers. Surgical treatment of upper gastric cancer by radical total gastrectomy achieved better survival radical proximal resection.
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![Survival of patients with upper gastric cancer and treated by total or proximal gastrectomy. (a) Invasion of the serosa, *p* = 0.045; (b) Borrmann type 3 or 4 infiltration, *p* = 0.028.](GRP2019-9248394.006){#fig6}

###### 

Clinicopathological characteristics of patients with upper and lower gastric cancer.

                                  Upper gastric cancer (%)   Lower gastric cancer (%)   *p* value
  ------------------------------- -------------------------- -------------------------- ------------
  Sex                                                                                   \<0.001
   Male                           531 (81.8)                 1098 (70.8)                
   Female                         118 (18.2)                 453 (29.2)                 
  Age (years)                                                                           0.003
   \<60                           303 (46.7)                 833 (53.7)                 
   ≥60                            346 (53.3)                 718 (46.4)                 
  Tumor diameter (cm)                                                                   \<0.001
   \<5                            267 (41.4)                 946 (61.0)                 
   ≥5                             382 (58.9)                 605 (39.0)                 
  Tissue type                                                                           0.046
   Well differentiated            270 (41.6)                 575 (37.1)                 
   Poorly differentiated          379 (58.4)                 976 (62.9)                 
  Tissue growth mode                                                                    \<0.001
   Agglomerate type               131 (20.2)                 434 (28.0)                 
   Nest type                      185 (28.0)                 467 (30.1)                 
   Diffuse type                   333 (25.7)                 650 (41.9)                 
  Macroscopic type                                                                      
   Early                          47 (7.2)                   332 (21.4)                 \<0.001^∗^
   Local (Borrmann 1, 2)          126 (19.4)                 212 (13.7)                 0.068^\#^
   Infiltrative (Borrmann 3, 4)   476 (73.4)                 1007 (64.9)                
  pT                                                                                    \<0.001
   T1                             47 (7.2)                   331 (21.3)                 
   T2                             67 (10.3)                  318 (20.5)                 
   T3                             271 (41.8)                 527 (34.0)                 
   T4a                            224 (34.5)                 340 (21.9)                 
   T4b                            40 (6.2)                   35 (2.3)                   
  pN                                                                                    0.041
   N0                             232 (35.7)                 639 (41.2)                 
   N1                             116 (17.9)                 299 (19.3)                 
   N2                             138 (21.3)                 284 (18.3)                 
   N3a                            110 (16.9)                 235 (15.2)                 
   N3b                            53 (8.2)                   94 (6.1)                   
  Lymphovascular tumor embolus                                                          0.034
   Positive                       172 (26.5)                 346 (22.3)                 
   Negative                       477 (73.5)                 1205 (77.7)                
  Serosal invasion                                                                      \<0.001
   Positive                       264 (40.7)                 375 (24.2)                 
   Negative                       385 (59.3)                 1176 (75.8)                
  Recurrence and metastasis                                                             \<0.001
   Positive                       277 (42.7)                 526 (33.9)                 
   Negative                       372 (57.3)                 1025 (66.1)                

^∗^Early versus advanced cancer; ^\#^comparison of advanced cancers.

###### 

Multivariate analysis of tumor characteristics and upper gastric cancer prognosis.

                              *B*      SE      Wald      *p*       RR      95% CI
  --------------------------- -------- ------- --------- --------- ------- --------------
  Macroscopic type            0.264    0.103   6.603     0.010     1.302   1.065--1.591
  Recurrence and metastasis   1.547    0.112   190.958   \<0.001   4.695   3.770--5.847
  Adjuvant chemotherapy       −0.548   0.112   24.078    \<0.001   0.578   0.464--0.719
  pTNM stage                  0.343    0.085   16.206    \<0.001   1.410   1.193--1.666

*B*: beta coefficient; SE: standard error of the mean; Wald: Wald statistic; RR: risk ratio; CI: confidence interval.

###### 

Patient characteristics and lymph node metastasis of upper gastric cancer.

                                  No metastasis   Metastasis   *p* value
  ------------------------------- --------------- ------------ -------------
  Sex                                                          0.011
   Male                           201             330          
   Female                         30              88           
  Age (years)                                                  0.936
   \<60                           107             195          
   ≥60                            124             223          
  Tumor diameter (cm)                                          \<0.001
   \<5                            126             141          
   ≥5                             105             277          
  Tissue typing                                                0.005
   Well differentiated            113             157          
   Poorly differentiated          118             261          
  Tissue growth mode                                           0.166
   Agglomerate type               52              79           
   Nest type                      72              113          
   Diffuse type                   107             226          
  Macroscopic type                                             
   Early                          39              8            \<0.001^∗^
   Local (Borrmann 1, 2)          65              61           \<0.001^\#^
   Infiltrative (Borrmann 3, 4)   127             349          
  pT                                                           \<0.001
   T1                             39              8            
   T2                             47              20           
   T3                             81              190          
   T4a                            55              165          
   T4b                            9               35           
  Lymphovascular cancer embolus                                0.180
   Positive                       54              118          
   Negative                       177             300          
  Serosal invasion                                             \<0.001
   Positive                       64              200          
   Negative                       167             218          
  Recurrence and metastasis                                    0.188
   Positive                       113             227          
   Negative                       118             191          

^∗^Early versus advanced cancer; ^\#^comparison of advanced cancers.

###### 

Multivariate analysis of tumor characteristics and lymph node metastasis in upper gastric cancer.

                     *B*      SE      Wald     *p* value   RR      95% CI
  ------------------ -------- ------- -------- ----------- ------- --------------
  Sex                −0.433   0.206   4.419    0.036       0.648   0.433--0.971
  Tumor diameter     0.570    0.166   11.837   0.001       1.768   1.278--2.447
  Macroscopic type   0.639    0.157   16.610   \<0.001     1.894   1.393--2.575
  pT stage           0.739    0.170   18.833   \<0.001     2.095   1.500--2.925
  Tissue typing      0.442    0.147   9.075    0.003       1.556   1.167--2.074
  Serosal invasion   −0.575   0.271   4.499    0.034       0.562   0.330--0.957

*B*: beta coefficient; SE: standard error of the mean; Wald: Wald statistic; RR: risk ratio; CI: confidence interval.

###### 

Patient characteristics and recurrence and metastasis of upper gastric cancer.

                                  Recurrence and metastasis   No recurrence and metastasis   *p* value
  ------------------------------- --------------------------- ------------------------------ -------------
  Sex                                                                                        0.246
   Male                           221                         310                            
   Female                         56                          62                             
  Age (years)                                                                                0.987
   \<60                           129                         173                            
   ≥60                            148                         199                            
  Tumor diameter (cm)                                                                        0.004
   \<5                            96                          171                            
   ≥5                             181                         201                            
  Tissue typing                                                                              0.099
   Well differentiated            105                         165                            
   Poorly differentiated          172                         207                            
  Tissue growth mode                                                                         0.473
   Agglomerate type               58                          73                             
   Nest type                      72                          113                            
   Diffuse type                   147                         186                            
  Macroscopic type                                                                           
   Early                          6                           41                             \<0.001^∗^
   Local (Borrmann 1, 2)          36                          90                             \<0.001^\#^
   Infiltrative (Borrmann 3, 4)   235                         241                            
  Lymphovascular cancer embolus                                                              0.003
   Positive                       90                          82                             
   Negative                       187                         290                            
  Serosal invasion                                                                           0.002
   Positive                       132                         132                            
   Negative                       145                         240                            
  Adjuvant chemotherapy                                                                      0.412
   Positive                       186                         261                            
   Negative                       91                          111                            
  pTNM stage                                                                                 \<0.001
   I                              16                          74                             
   II                             58                          156                            
   III                            203                         142                            

^∗^Early versus advanced cancer; ^\#^comparison of advanced cancers.

###### 

Multivariate analysis of tumor characteristics and recurrence and metastasis of upper gastric cancer.

                                *B*     SE      Wald     *p* value   RR      95% CI
  ----------------------------- ------- ------- -------- ----------- ------- --------------
  Macroscopic type              0.379   0.189   4.003    0.045       1.460   1.008--2.116
  Lymphovascular tumor emboli   0.440   0.191   5.287    0.021       1.552   1.067--2.258
  pTNM typing                   0.966   0.149   42.105   \<0.001     2.628   1.963--3.519

*B*: beta coefficient; SE: standard error of the mean; Wald: Wald statistic; RR: risk ratio; CI: confidence interval.

###### 

One-, 3-, and 5-year survival of upper gastric cancer patients with total or proximal gastrectomy.

                     Total gastrectomy   Proximal gastrectomy   *p*                                      
  ------------------ ------------------- ---------------------- ------ ------ ----- ------ ------ ------ -------
                     333                 81.3                   54.4   45.2   316   75.4   44.9   36.7   0.029
  TNM stage                                                                                              
   I                 37                  84.9                   71.7   65.9   53    94.6   83.8   75.4   0.385
   II                79                  86.7                   60.0   53.3   135   81.0   69.4   59.3   0.305
   III               217                 74.2                   41.4   28.1   128   68.7   29.5   24.1   0.112
  Macroscopic type                                                                                       
   Early             22                  96.0                   88.0   79.1   25    90.9   86.4   76.4   0.350
   Local             45                  81.5                   56.8   45.7   81    88.9   64.4   59.2   0.309
   Infiltrative      266                 79.5                   49.0   40.0   210   70.7   38.2   29.2   0.028
  Tumor diameter                                                                                         
   \<5 cm            115                 91.9                   85.1   62.8   148   82.3   57.7   47.0   0.258
   ≥5 cm             214                 78.0                   47.0   36.9   168   70.1   37.9   31.0   0.194
  Serosal invasion                                                                                       
   Positive          164                 81.4                   57.0   48.4   221   78.6   55.3   44.1   0.689
   Negative          169                 81.1                   48.4   37.9   95    70.4   34.9   27.3   0.045

[^1]: Academic Editor: Fausto Rosa
